Cargando…

Exploring the Value of BRD9 as a Biomarker, Therapeutic Target and Co-Target in Prostate Cancer

Background and aims: Despite recent advances in advanced prostate cancer treatments, clinical biomarkers or treatments for men with such cancers are imperfect. Targeted therapies have shown promise, but there remain fewer actionable targets in prostate cancer than in other cancers. This work aims to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Barma, Nafisa, Stone, Timothy C., Carmona Echeverria, Lina Maria, Heavey, Susan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8698755/ https://www.ncbi.nlm.nih.gov/pubmed/34944438 http://dx.doi.org/10.3390/biom11121794

Ejemplares similares

Targeting BRD9 by I-BRD9 efficiently inhibits growth of acute myeloid leukemia cells
por: Zhou, Lixin, et al.
Publicado: (2021)

BRD4: An emerging prospective therapeutic target in glioma
por: Yang, Hua, et al.
Publicado: (2021)

BRD4 as a Therapeutic Target in Pulmonary Diseases
por: Guo, Xia, et al.
Publicado: (2023)

Targeting BRD9 for Cancer Treatment: A New Strategy
por: Zhu, Xiuzuo, et al.
Publicado: (2020)

Post-Translational Modifications of BRD4: Therapeutic Targets for Tumor
por: Liu, Na, et al.
Publicado: (2022)

PIM kinase inhibition: co-targeted therapeutic approaches in prostate cancer
por: Luszczak, Sabina, et al.
Publicado: (2020)

Theoretical exploration of the binding selectivity of inhibitors to BRD7 and BRD9 with multiple short molecular dynamics simulations
por: Wang, Lifei, et al.
Publicado: (2022)

Therapeutic Targeting of BRD4 in Head Neck Squamous Cell Carcinoma
por: Wu, Yaping, et al.
Publicado: (2019)

Targeted degradation of BRD9 reverses oncogenic gene expression in synovial sarcoma
por: Brien, Gerard L, et al.
Publicado: (2018)

Evaluating the bromodomain protein BRD1 as a therapeutic target in rheumatoid arthritis
por: Klein, Kerstin, et al.
Publicado: (2018)

BRD4 as a therapeutic target for nonfunctioning and growth hormone pituitary adenoma
por: Shi, Chengzhang, et al.
Publicado: (2020)

Targeting Mechanotransduction at the Transcriptional Level: YAP and BRD4 Are Novel Therapeutic Targets for the Reversal of Liver Fibrosis
por: Zhubanchaliyev, Altynbek, et al.
Publicado: (2016)

Preclinical and Toxicology Studies of BRD5529, a Selective Inhibitor of CARD9
por: Kottom, Theodore J., et al.
Publicado: (2022)

Combined targeting of HEDGEHOG signaling and BRD4 as a novel therapeutic option against melanoma
por: Pietrobono, Silvia, et al.
Publicado: (2023)

Exploring the Wnt Pathway as a Therapeutic Target for Prostate Cancer
por: Koushyar, Sarah, et al.
Publicado: (2022)

Bone Scan Is of Doubtful Value as a First Staging Test in the Primary Presentation of Prostate Cancer
por: Carmona Echeverria, Lina M., et al.
Publicado: (2012)

BRD4/8/9 are prognostic biomarkers and associated with immune infiltrates in hepatocellular carcinoma
por: Chen, Yi-Ru, et al.
Publicado: (2020)

BET inhibitor OTX015 targets BRD2 and BRD4 and decreases c-MYC in acute leukemia cells
por: Coudé, Marie-Magdelaine, et al.
Publicado: (2015)

BRD4: A BET(ter) target for the treatment of AML?
por: Valent, Peter, et al.
Publicado: (2014)

Bardoxolone conjugation enables targeted protein degradation of BRD4
por: Tong, Bingqi, et al.
Publicado: (2020)

Targeting the ERG oncogene with splice-switching oligonucleotides as a novel therapeutic strategy in prostate cancer
por: Li, Ling, et al.
Publicado: (2020)

BRD9 Inhibition by Natural Polyphenols Targets DNA Damage/Repair and Apoptosis in Human Colon Cancer Cells
por: Kapoor, Sabeeta, et al.
Publicado: (2022)

Exploration and Validation of Potential Biomarkers and Therapeutic Targets in Ferroptosis of Asthma
por: Xing, Yanqing, et al.
Publicado: (2023)

BRD9 degraders as chemosensitizers in acute leukemia and multiple myeloma
por: Weisberg, Ellen, et al.
Publicado: (2022)

BRD9 Inhibition, Alone or in Combination with Cytostatic Compounds as a Therapeutic Approach in Rhabdoid Tumors
por: Krämer, Katja F., et al.
Publicado: (2017)

Inflammation in prostate cancer progression and therapeutic targeting
por: Stark, Timothy, et al.
Publicado: (2015)

Targeting BRD4 prevents acute gouty arthritis by regulating pyroptosis
por: Hao, Kun, et al.
Publicado: (2020)

Co-targeting PIM and PI3K/mTOR using multikinase inhibitor AUM302 and a combination of AZD-1208 and BEZ235 in prostate cancer
por: Luszczak, Sabina, et al.
Publicado: (2020)

Alternative polyadenylation: An untapped source for prostate cancer biomarkers and therapeutic targets?
por: Kurozumi, Akira, et al.
Publicado: (2021)

BRD9 regulates interferon-stimulated genes during macrophage activation via cooperation with BET protein BRD4
por: Ahmed, Nasiha S., et al.
Publicado: (2021)

Author Correction: Co-targeting PIM and PI3K/mTOR using multikinase inhibitor AUM302 and a combination of AZD-1208 and BEZ235 in prostate cancer
por: Luszczak, Sabina, et al.
Publicado: (2020)

Combined BRD4 and CDK9 inhibition as a new therapeutic approach in malignant rhabdoid tumors
por: Moreno, Natalia, et al.
Publicado: (2017)

Transcriptome analysis of dominant-negative Brd4 mutants identifies Brd4-specific target genes of small molecule inhibitor JQ1
por: Decker, Tim-Michael, et al.
Publicado: (2017)

Epigenetic and pharmacological control of pigmentation via Bromodomain Protein 9 (BRD9)
por: Basuroy, Tupa, et al.
Publicado: (2022)

BRD4-mediated repression of p53 is a target for combination therapy in AML
por: Latif, Anne-Louise, et al.
Publicado: (2021)

BRD4-targeting PROTAC as a unique tool to study biomolecular condensates
por: Shi, Yi, et al.
Publicado: (2023)

BRD9 Degradation Disrupts Ribosome Biogenesis in Multiple Myeloma
por: Kurata, Keiji, et al.
Publicado: (2023)

Identification of biomarkers, pathways and potential therapeutic target for docetaxel resistant prostate cancer
por: Liu, Rui-ji, et al.
Publicado: (2021)

Editorial: Identification of therapeutic targets and novel biomarkers in prostate cancer volume II
por: Sharad, Shashwat, et al.
Publicado: (2023)

Exploring potential biomarkers and therapeutic targets of long COVID-associated inflammatory cardiomyopathy
por: Qi, Peng, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_04luiro77uueocsdppb2p7cofb